Industry
Biotechnology
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Loading...
Open
8.85
Mkt cap
842M
Volume
1.4M
High
8.85
P/E Ratio
-2.68
52-wk high
16.63
Low
7.85
Div yield
N/A
52-wk low
7.00
Portfolio Pulse from
November 15, 2024 | 1:15 pm
Portfolio Pulse from
November 13, 2024 | 5:15 am
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 12:43 pm
Portfolio Pulse from Benzinga Newsdesk
September 20, 2024 | 4:14 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 5:11 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 12:44 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 10:42 am
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 8:34 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.